PLEASANTON, Calif., Aug. 8, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its second quarter, which ended July 31, 2023, after market close on August 30, 2023. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results.
Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event.
Event: | Veeva's Fiscal 2024 Second Quarter Results Conference Call |
Date: | Wednesday, August 30, 2023 |
Time: | 2:00 p.m. PT (5:00 p.m. ET) |
Conference Call Registration: | |
Webcast: |
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | ||
Gunnar Hansen Veeva Systems Inc. 267-460-5839 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Media Contact: | |
Maria Scurry | |
Veeva Systems Inc. | |
781-366-7617 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$224.15 |
Daily Change: | 4.48 2.04 |
Daily Volume: | 1,465,186 |
Market Cap: | US$36.390B |
December 05, 2024 November 24, 2024 November 20, 2024 November 19, 2024 October 24, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB